Navigation Links
Annual Trachoma Treatments May Be Unnecessary
Date:4/23/2008

One or 2 rounds of antibiotics sufficient to treat eye disease, study finds

WEDNESDAY, April 23 (HealthDay News) -- In communities with moderate levels of the eye disease trachoma, one or two rounds of high coverage mass treatment with the antibiotic azithromycin may be sufficient to eliminate the infection, researchers say.

A team at the London School of Hygiene & Tropical Medicine's Trachoma Group said its findings challenge the World Health Organization's recommendation for annual antibiotic treatment and called for a re-evaluation of how communities affected with trachoma are treated.

The five-year study was conducted in Kahe Mpya, Tanzania. After an initial round of mass treatment (97.6 percent of residents) with single-dose azithromycin, the prevalence of trachoma decreased from 9.5 percent to 0.1 percent after two years.

A second round of mass treatment was carried out two years after the first round. Three years after the second round of mass treatment, trachoma DNA was not detected in the eyes of any of the 859 people who were checked, which suggested the infection had been eliminated.

A letter outlining the findings was published in the April 24 issue of the New England Journal of Medicine.

Currently, the WHO recommends three years of annual mass azithromycin treatment before reassessment in communities where 10 percent or more of children ages 1 to 9 have trachoma.

"Had WHO recommendations on antibiotic use been followed, three or possibly six annual rounds of mass treatment would have been offered in this community, whereas our data suggest that one round was sufficient," noted Dr. Anthony Solomon, lead author of the letter. "The less antibiotic we can use in each community, the more people we'll be able to use donated antibiotic for, and the lower the likelihood of the emergence of antibiotic-resistant strains."

More information

T
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
2. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
3. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
4. Bear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation
5. inVentiv Health to Present at the 20th Annual Bear Stearns Healthcare Conference
6. Annual flu shot cuts need for doctors visits, hospitalization among children
7. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
8. Johnson & Johnson to Participate in Bear Stearns 20th Annual Healthcare Conference
9. Chem Rx to Present at Bear Stearns 20th Annual Healthcare Conference
10. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
11. CuraGen to Present at the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Beverage Can Stay Tabs Pose Swallowing Risk 62223 1Beverage Can Stay Tabs Pose Swallowing Risk 62223 2New Class of Platinum Based Anti Tumor Drugs Bisplatinates Demonstrates Potent Anti Tumor Activity and Ability to Overcome Resistance to Currently A 14993 1New Class of Platinum Based Anti Tumor Drugs Bisplatinates Demonstrates Potent Anti Tumor Activity and Ability to Overcome Resistance to Currently A 14993 2New Class of Platinum Based Anti Tumor Drugs Bisplatinates Demonstrates Potent Anti Tumor Activity and Ability to Overcome Resistance to Currently A 14993 3Elsevier is Re Launching 26quot 3BEmbase 26quot 3B to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 14989 1Elsevier is Re Launching 26quot 3BEmbase 26quot 3B to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 14989 2Elsevier is Re Launching 26quot 3BEmbase 26quot 3B to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 14989 3